- Home
- RYDE vs ADXN Comparison
RYDE vs ADXN Comparison
Compare RYDE & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- ADXN
- Stock Information
- Founded
- RYDE 2014
- ADXN 2002
- Country
- RYDE Singapore
- ADXN Switzerland
- Employees
- RYDE N/A
- ADXN N/A
- Industry
- RYDE
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- ADXN Health Care
- Exchange
- RYDE NYSE
- ADXN Nasdaq
- Market Cap
- RYDE 5.2M
- ADXN 10.1M
- IPO Year
- RYDE 2024
- ADXN N/A
- Fundamental
- Price
- RYDE $0.30
- ADXN $8.30
- Analyst Decision
- RYDE
- ADXN Strong Buy
- Analyst Count
- RYDE 0
- ADXN 1
- Target Price
- RYDE N/A
- ADXN $30.00
- AVG Volume (30 Days)
- RYDE 701.3K
- ADXN 4.2K
- Earning Date
- RYDE 05-02-2025
- ADXN 08-11-2025
- Dividend Yield
- RYDE N/A
- ADXN N/A
- EPS Growth
- RYDE N/A
- ADXN N/A
- EPS
- RYDE N/A
- ADXN 0.10
- Revenue
- RYDE $6,557,978.00
- ADXN $278,508.00
- Revenue This Year
- RYDE $21.13
- ADXN $86.57
- Revenue Next Year
- RYDE $13.43
- ADXN N/A
- P/E Ratio
- RYDE N/A
- ADXN $0.71
- Revenue Growth
- RYDE 3.27
- ADXN N/A
- 52 Week Low
- RYDE $0.16
- ADXN $6.51
- 52 Week High
- RYDE $22.49
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- ADXN 46.61
- Support Level
- RYDE N/A
- ADXN $8.05
- Resistance Level
- RYDE N/A
- ADXN $8.57
- Average True Range (ATR)
- RYDE 0.00
- ADXN 0.28
- MACD
- RYDE 0.00
- ADXN -0.05
- Stochastic Oscillator
- RYDE 0.00
- ADXN 47.72
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.